Tinzaparin is an antithrombotic in the heparin group. It is a low-molecular-weight heparin with 4500 daltons in average. It has been approved by the FDA for once-daily treatment of deep vein thrombosis and pulmonary embolism . more

Tinzaparin is an antithrombotic in the heparin group. It is a low-molecular-weight heparin with 4500 daltons in average. It has been approved by the FDA for once-daily treatment of deep vein thrombosis and pulmonary embolism . [ 1 ]

In July 2008, the company revised the prescribing information to restrict the use of Innohep in patients 90 years of age or older. FDA is concerned that the preliminary data from the IRIS study suggest that the increased risk of mortality is not limited only to patients 90 years of age or older. Therefore, FDA has requested that the company revise the labeling for Innohep to better describe the overall study results which suggest that, when compared to unfractionated heparin, Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with renal insufficiency. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with renal insufficiency and DVT, PE, or both. This communication is in keeping with FDA?s commitment to inform the public about its ongoing safety reviews of drugs. FDA anticipates submission of the final IRIS study report in January, 2009 and plans to complete its review soon thereafter. FDA will communicate its conclusions and any resulting recommendations to the public at that time. FDA will consider additional regulatory actions as appropriate after thorough review of all applicable data from the manufacturer of Innohep. less